Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease- Cognition (SCOPA-Cog)

Isella, Valeria; Mapelli, Cristina; Morielli, N.; Gaspari, Danilo De; Siri, Chiara; Pezzoli, Gianni; Antonini, Angelo; Poletti, Michele; Bonuccelli, Ubaldo; Picchi, Lucia; Napolitano, Alessandro; Vista, Marco; Veglia, Maia; Piamarta, F.; Grassi, F.; Appollonio, Ildebrando

doi:10.11138/fneur/2013.28.1.121

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different cutoffs have been proposed; a score < 20 points yielded a sensitivity of 85% and specificity of 96% for PD‐D . In another study, a score of <24 points differentiated PD‐MCI level I versus normal controls with a sensitivity of 90% and specificity of 73%, and a score of <17 points differentiated PD‐MCI from PD‐D with a sensitivity of 93% and specificity of 97% …”

Section: Resultsmentioning

confidence: 99%

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The Montreal Cognitive Assessment [41] was shown to be superior to other widely used clinical tools, such as the Mini-Mental State exam in that it lacks floor or ceiling effects [30]. Other neuropsychiatric tools are validated as progression measures: the Neuropsychiatric Inventory [42], Scales for Outcomes in PD-Cognition [43], the Beck Depression Scale and the Geriatric Depression Scale [44]. It is clear that clinical measures such as smell testing and sleep disorders, when added to other assessments such as genetic risk score, can be a useful component in predicting PD risk [19].…”

Section: Clinical Biomarkersmentioning

confidence: 99%

Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program

et al. 2017

View full text Add to dashboard Cite

Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.

show abstract

Cognitive and behavioral disorders in Parkinson’s disease: an update. I: cognitive impairments

Papagno

Trojano

2017

Neurol Sci

View full text Add to dashboard Cite

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by motor symptoms such as rigidity, rest tremor, and bradykinesia. However, a growing body of evidence demonstrated that PD encompasses several non-motor disturbances as well, such as cognitive impairment. Cognitive defects can be present since early stages of the disease but tend to dominate the clinical picture as the disease progresses. Around 40% of patients with PD present with cognitive impairments in several cognitive domains including attention, working memory and executive functions, language, visuospatial skills, and episodic memory; in later stages of the disease, cognitive defects and associated behavioral disorders concur to determine clinically relevant PD-associated dementia. Part of these defects is ascribed to a dopamine-dependent dysfunction of fronto-striatal pathways, but there is a considerable heterogeneity in the cognitive impairments as well as a suggestion of the role of other neurotransmitter systems, such as the cholinergic one, mainly responsible for Parkinson-dementia syndrome. In this paper, we review recent literature with particular attention to the last 5 years on the main cognitive deficits described in PD patients as well as on the hypothesized neuro-functional substrate of such impairments. Finally, we provide some suggestions on how to test cognitive functions in PD appropriately.

show abstract

Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease- Cognition (SCOPA-Cog)

Cited by 4 publications

References 17 publications

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations

Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program

Cognitive and behavioral disorders in Parkinson’s disease: an update. I: cognitive impairments

Contact Info

Product

Resources

About